Drug giants agree to settle pricing suit

Article Abstract:

Hoechst Marion Roussel, a unit of Hoechst AG of Germany, Pharmacia & Upjohn Inc., Abbott Laboratories and Rhone-Poulenc Rorer Inc., the pharmaceutical unit of France's Rhone-Poulenc SA, have agreed to pay around $350 million to settle class-action price fixing litigation. The case was filed by thousands of independent US pharmacies and drugstore chains. US District Judge Charles Kocoras in Chicago, IL, who is overseeing the litigation, needs to approve the terms of the agreement. The settlement would cover numerous lawsuits filed starting in 1993 and consolidated into one action.

Comment:

Along with 3 other drug giants, agreea to pay around $350 mil to settle class-action price fixing litigation

Government regulation (cont), Pharmaceutical Preparations, Pharmacia and Upjohn Inc., Rhone-Poulenc Rorer Inc., Hoechst Marion Roussel Inc., Article

---

Baxter concedes its filters do figure in patients' deaths; inquiry finds some fluid used to test dialyzers failed to evaporate

Article Abstract:

Illinois-based Baxter International Inc. admits that its dialysis filters and a chemical used in testing for leaks may have contributed to the deaths of 51 people internationally. The United States' Food and Drug Administration is investigating two deaths in Texas, 10 in Spain, four in Italy, five in Germany, 21 in Croatia and seven in Taiwan. The chemical was made by 3M, the filters in Sweden, the fibers in Florida.

Legal issues & crime, International, Medical Instruments and Supplies, Medical Equipment and Supplies Manufacturing, Medical Instruments & Supplies, Pharmaceutical industry, Investigations, Medical equipment and supplies industry, Medical equipment industry, United States. Food and Drug Administration, Wrongful death, Baxter International Inc. (Deerfield, Illinois), BAX

---

Boehringer to share Mobic rights in U.S

Article Abstract:

Abbot Laboratories has purchased the co-marketing rights in the US for the Mobic drug. Mobic represents one of a new class of pain medications that are generally named "Cox-2 inhibitors." Boehringer Ingelheim GmbH, which manufactures Mobic, will sell the drug together. The marketing agreement with Boehringer reflects the increasingly-aggressive style of Miles D. White, the new CEO of Abbot.

Comment:

Abbot Laboratories to co-market Mobic drug with Boehringer

Foreign operations, Germany, Pharmaceutical preparations, Strategic alliances, Central Nervous System Prep, Abstract, Central nervous system agents, ABT, Boehringer Ingelheim GmbH

Similar abstracts:

• Abstracts: Nortel Networks to pay $2.4 billion to settle suits. Nortel expects to post a loss of $3.6 billion. Corning, Nortel scuttle talks on possible merger
• Abstracts: Shaw suing Telus over cable ads. Mobile magazine. Two bid for multinlingual TV licence
• Abstracts: Brains against brains. Vancouver TV sales still going strong. Cheeky ads push track attendance
• Abstracts: Reebok's probe faults Indonesian plants. Hasbro to cut work force by 19% in restructuring. G.I. Joe is there as toyland issues a call to arms; now it's okay to play with guns and soldiers
• Abstracts: 'No more fishing blind'. French doors cope with abrasive grounds. Cableless gear sensors use retractable antenna

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.